There is an ongoing clinical trial (NCT02978196) aiming to evaluate the safety, dosimetry, and efficacy of an 99mTc-labeled anti-PD-L1 nanobody in non-small cell lung cancer (NSCLC) (Figure 5) [98]. Here, CD274 is linked to non-small cell lung carcinoma.